摘要:
The invention relates to compounds of formula (I), to their enantiomers, diastereoisomers, N-oxides, as well as to their pharmaceutically acceptable acid or base addition salts. The inventive compounds are hydroxylase tyrosine inducers.
摘要:
The invention relates to compounds of formula (I), to their enantiomers, diastereoisomers, N-oxides, as well as to their pharmaceutically acceptable acid or base addition salts. The inventive compounds are hydroxylase tyrosine inducers.
摘要:
The invention relates to compounds of the formula (I) the enantiomers, diastereoisomers, N-oxides and addition salts thereof with a pharmaceutically acceptable acid or base. The compionds of formula (I) are tyrosine hydroxylase inductors.
摘要:
The invention relates to compounds of formula (I), to their enantiomers, diastereoisomers, and N-oxides, as well as to their addition salts to a pharmaceutically acceptable acid or base. The compounds according to the invention are powerful tyrosine hydroxylase inducers.
摘要:
The invention relates to compounds of the formula (I) the enantiomers, diastereoisomers, N-oxides and addition salts thereof with a pharmaceutically acceptable acid or base. The compionds of formula (I) are tyrosine hydroxylase inductors.
摘要:
La présente invention concerne des composés inhibiteurs de la polymérisation de la tubuline, leurs procédés de préparation ainsi que leurs utilisations.
摘要:
The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.
摘要:
The present invention relates to the design of new molecules, referred to as "multi-target" molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDAC) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the "multi-target" molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one "multi-target" molecule, and the use of such compositions in the treatment of cancer.